1 Result(s)

Article

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respo...

Steven P. Angus, Timothy J. Stuhlmiller, Gaurav Mehta… in npj Breast Cancer (2021)